Phase 1 Efficacy and Pharmacodynamic Results of Exicorilant + Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
Michael Morris et al. • 2023 • ASCO GU Cancers Symposium 2023
© 2024 Corcept Therapeutics, Incorporated
Glucocorticoid Receptor Antagonism Upregulates Somatostatin Receptor Subtype 2 Expression in ACTH-Producing Neuroendocrine Tumors: New Insight Based on the Selective Glucocorticoid Receptor Modulator Relacorilant
Pivonello et al • 2022 • Front. Endocrinol.
Phase 2 Results of Relacorilant + Nab-Paclitaxel in Patients with Recurrent, Platinum-resistant Ovarian Cancer with and Without Prior Bevacizumab
Colombo et al • 2022 • International Gynecologic Cancer Society 2022 Annual Meeting
Glucocorticoid Receptor Expression and Activity in a Phase 2 Ovarian Cancer Trial of the Glucocorticoid Receptor Modulator Relacorilant in Combination with Nab-Paclitaxel
Lorusso et al • 2022 • European Society for Medical Oncology (ESMO) Congress 2022
Phase 1 Results of Exicorilant + Enzalutamide in Patients with Castration-Resistant Prostate Cancer
Linch et al • 2022 • European Society for Medical Oncology (ESMO) Congress 2022
Relacorilant + Nab-paclitaxel in Patients with Recurrent, Platinum-resistant Ovarian Cancer: Phase 2 Subgroup Analysis Mirroring the Patient Population of an Upcoming Phase 3 Study
Colombo et al • 2022 • European Society for Medical Oncology (ESMO) Congress 2022
Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors
Munster et al • 2022 • Clin Cancer Res OF1–OF11
Favorable liver safety profile of the selective glucocorticoid receptor modulator relacorilant in healthy and hepatically impaired adults and in patients with Cushing Syndrome
Moraitis et al • 2022 • ENDO 2022 Annual Meeting
Impact of mifepristone on liver function and liver steatosis in patients with Cushing Syndrome
East et al • 2022 • ENDO 2022 Annual Meeting
Overall survival data from a 3-arm, randomized, open-label phase 2 study of relacorilant, a selective glucocorticoid receptor modulator, combined with nab-paclitaxel in patients with recurrent platinum-resistant ovarian cancer
Colombo et al • 2022 • American Society of Clinical Oncology Annual Meeting